Results 41 to 50 of about 3,351 (178)
Clinical and Translational Science, 2021 Zanubrutinib is a potent, second‐generation Bruton’s tyrosine kinase inhibitor that is currently being investigated in patients with B‐cell malignancies and recently received accelerated approval in the United States for treatment of relapsed/refractory ...
Ying C. Ou +7 more
doaj +1 more source
Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia
Cells, 2022 Waldenström macroglobulinemia (WM) is a rare form of non-Hodgkin B-cell lymphoma with a variable clinical presentation that can impact a patient’s quality of life by causing anemia, peripheral neuropathy, serum hyperviscosity, extramedullary disease, and
Javier Muñoz +3 more
doaj +1 more source
Technology in Cancer Research & Treatment, 2022 Background and Objects: Bruton's tyrosine kinase inhibitors are commonly used and effective for lymphoma and chronic lymphocytic leukemia (CLL). Ibrutinib might improve the effect of anti-cluster of differentiation 19 (CD19) chimeric antigen receptor ...
Xiupeng Ye +7 more
doaj +1 more source
Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner
Pharmaceutics, 2022 BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu +6 more
doaj +1 more source
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study [PDF]
, 2020 Se trata de la publicación del estudio de fase 3 ASPEN que comparó en pacientes con macro-globulinemia de Waldenström (WM) la eficacia y la seguridad de ibrutinib, un inhibidor de la tirosi-na quinasa Bruton (BTK) de primera generación, familia que ha ...
Belada, David +32 more
core +1 more source
Frontiers in Oncology, 2021 Vitreoretinal lymphoma (VRL) is a rare intraocular malignancy, and standard treatment approaches have not been defined yet. Bruton tyrosine kinase inhibitors are found to be effective in the treatment of primary central nervous system diffuse large B ...
Liang Wang, Wenxue Guan, Xiaoyan Peng
doaj +1 more source
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. [PDF]
, 2021 Novel targeted cancer therapies have revolutionized oncology therapies, but these treatments can have cardiovascular complications, which include heterogeneous cardiac, metabolic, and vascular sequelae.
Barac, Ana +5 more
core +1 more source
Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib
Journal of Neurological Surgery Reports, 2022 Spontaneous spinal subdural hematomas (SSH) are rare occurrences that can occur most commonly secondary to vascular malformations or coagulopathies. Only a small fraction of spontaneous SSHs are caused by acquired coagulation disorders such as leukemia ...
John Lynes +7 more
doaj +3 more sources
Zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA [PDF]
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
et al.,, Kahl, Brad S, Shadman, Mazyar
core +5 more sources
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib [PDF]
Bruton tyrosine kinase (BTK), the primary target of BTK inhibitors, is a key enzyme in the proliferation and survival pathway of neoplastic B-cells. BTK inhibitors are approved in many hematologic malignancies: chronic lymphocytic leukaemia, mantle cell ...
Broccoli, Alessandro +3 more
core +1 more source